您的账号已在其他设备登录,您当前账号已强迫下线,
如非您本人操作,建议您在会员中心进行密码修改

确定
收藏 | 浏览30

Knowledge gathered during the past few decades from the fields of cancer epidemiology, carcinogenesis, biochemistry, and molecular biology, much of which was communicated through the pages of the journal Cancer Research, provides powerful new strategies for cancer prevention. Indeed, I believe that it is possible to draft a blueprint for a comprehensive approach to cancer prevention, to be used as we approach the 21st century. This plan includes: (a) expanded epidemiological and laboratory studies to identify the specific causes of human cancers; (b) intervention studies, such as risk reduction by the cessation of cigarette smoking, dietary modifications, chemoprevention, and the development of vaccines for viral agents implicated in human cancer (i.e., hepatitis B, human papilloma virus, Epstein-Barr virus, and certain retroviruses), and (c) early detection and screening. Concepts and methods that have developed in the field of cellular and molecular biology will accelerate this progress. Indeed, we are currently in a very exciting phase of cancer research that brings together fields of cancer research which in the past were often disparate and disconnected, i.e., basic laboratory studies, epidemiology, prevention, and treatment. Thus, the astounding advances in our understanding of the molecular biology of cancer provide a unified concept of the nature of the cancer cell and also suggest new clinical approaches to cancer etiology, prevention, and treatment. Many of the biomarkers being developed for etiological studies, using the approach of molecular epidemiology, can also serve as biomarkers or intermediate end points to evaluate the efficacy of dietary intervention and chemoprevention studies. Some of these biomarkers will also be useful for evaluating the efficacy of cancer therapy. Furthermore, certain compounds being developed for cancer chemoprevention, e.g., the retinoids, may also be useful in the therapy of fully established neoplasms. It seems likely, therefore, that even before the year 2000 these powerful and unifying themes will accelerate advances in both cancer prevention and treatment, thus leading to major reductions in both the incidence and mortality of human cancer.

作者:I B, Weinstein

来源:Cancer research 1991 年 51卷 18 Suppl期

知识库介绍

临床诊疗知识库该平台旨在解决临床医护人员在学习、工作中对医学信息的需求,方便快速、便捷的获取实用的医学信息,辅助临床决策参考。该库包含疾病、药品、检查、指南规范、病例文献及循证文献等多种丰富权威的临床资源。

详细介绍
热门关注
免责声明:本知识库提供的有关内容等信息仅供学习参考,不代替医生的诊断和医嘱。

收藏
| 浏览:30
作者:
I B, Weinstein
来源:
Cancer research 1991 年 51卷 18 Suppl期
Knowledge gathered during the past few decades from the fields of cancer epidemiology, carcinogenesis, biochemistry, and molecular biology, much of which was communicated through the pages of the journal Cancer Research, provides powerful new strategies for cancer prevention. Indeed, I believe that it is possible to draft a blueprint for a comprehensive approach to cancer prevention, to be used as we approach the 21st century. This plan includes: (a) expanded epidemiological and laboratory studies to identify the specific causes of human cancers; (b) intervention studies, such as risk reduction by the cessation of cigarette smoking, dietary modifications, chemoprevention, and the development of vaccines for viral agents implicated in human cancer (i.e., hepatitis B, human papilloma virus, Epstein-Barr virus, and certain retroviruses), and (c) early detection and screening. Concepts and methods that have developed in the field of cellular and molecular biology will accelerate this progress. Indeed, we are currently in a very exciting phase of cancer research that brings together fields of cancer research which in the past were often disparate and disconnected, i.e., basic laboratory studies, epidemiology, prevention, and treatment. Thus, the astounding advances in our understanding of the molecular biology of cancer provide a unified concept of the nature of the cancer cell and also suggest new clinical approaches to cancer etiology, prevention, and treatment. Many of the biomarkers being developed for etiological studies, using the approach of molecular epidemiology, can also serve as biomarkers or intermediate end points to evaluate the efficacy of dietary intervention and chemoprevention studies. Some of these biomarkers will also be useful for evaluating the efficacy of cancer therapy. Furthermore, certain compounds being developed for cancer chemoprevention, e.g., the retinoids, may also be useful in the therapy of fully established neoplasms. It seems likely, therefore, that even before the year 2000 these powerful and unifying themes will accelerate advances in both cancer prevention and treatment, thus leading to major reductions in both the incidence and mortality of human cancer.